Logo image of PGEN

PRECIGEN INC (PGEN) Stock Fundamental Analysis

NASDAQ:PGEN - Nasdaq - US74017N1054 - Common Stock - Currency: USD

1.905  -0.02 (-1.3%)

Fundamental Rating

2

Taking everything into account, PGEN scores 2 out of 10 in our fundamental rating. PGEN was compared to 571 industry peers in the Biotechnology industry. PGEN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, PGEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PGEN has reported negative net income.
PGEN had a negative operating cash flow in the past year.
PGEN had negative earnings in 4 of the past 5 years.
In the past 5 years PGEN always reported negative operating cash flow.
PGEN Yearly Net Income VS EBIT VS OCF VS FCFPGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M -400M -500M

1.2 Ratios

PGEN's Return On Assets of -167.19% is on the low side compared to the rest of the industry. PGEN is outperformed by 85.64% of its industry peers.
Looking at the Return On Equity, with a value of -252.03%, PGEN is doing worse than 70.75% of the companies in the same industry.
Industry RankSector Rank
ROA -167.19%
ROE -252.03%
ROIC N/A
ROA(3y)-25.34%
ROA(5y)-40.18%
ROE(3y)-48.15%
ROE(5y)-169.54%
ROIC(3y)N/A
ROIC(5y)N/A
PGEN Yearly ROA, ROE, ROICPGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

1.3 Margins

PGEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PGEN Yearly Profit, Operating, Gross MarginsPGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

PGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PGEN has more shares outstanding
The number of shares outstanding for PGEN has been increased compared to 5 years ago.
There is no outstanding debt for PGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PGEN Yearly Shares OutstandingPGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
PGEN Yearly Total Debt VS Total AssetsPGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -26.19, we must say that PGEN is in the distress zone and has some risk of bankruptcy.
PGEN has a worse Altman-Z score (-26.19) than 88.09% of its industry peers.
PGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.19
ROIC/WACCN/A
WACC9.12%
PGEN Yearly LT Debt VS Equity VS FCFPGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.63 indicates that PGEN should not have too much problems paying its short term obligations.
The Current ratio of PGEN (1.63) is worse than 80.21% of its industry peers.
A Quick Ratio of 1.63 indicates that PGEN should not have too much problems paying its short term obligations.
PGEN has a worse Quick ratio (1.63) than 79.16% of its industry peers.
Industry RankSector Rank
Current Ratio 1.63
Quick Ratio 1.63
PGEN Yearly Current Assets VS Current LiabilitesPGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

PGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.51%.
Looking at the last year, PGEN shows a very negative growth in Revenue. The Revenue has decreased by -41.38% in the last year.
Measured over the past years, PGEN shows a very negative growth in Revenue. The Revenue has been decreasing by -47.17% on average per year.
EPS 1Y (TTM)-13.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)-41.38%
Revenue growth 3Y-60.78%
Revenue growth 5Y-47.17%
Sales Q2Q%-30.89%

3.2 Future

PGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.74% yearly.
Based on estimates for the next years, PGEN will show a very strong growth in Revenue. The Revenue will grow by 125.76% on average per year.
EPS Next Y-21.88%
EPS Next 2Y20.88%
EPS Next 3Y30.58%
EPS Next 5Y24.74%
Revenue Next Year-38.3%
Revenue Next 2Y79.23%
Revenue Next 3Y188.95%
Revenue Next 5Y125.76%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PGEN Yearly Revenue VS EstimatesPGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
PGEN Yearly EPS VS EstimatesPGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PGEN Price Earnings VS Forward Price EarningsPGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PGEN Per share dataPGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as PGEN's earnings are expected to grow with 30.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.88%
EPS Next 3Y30.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRECIGEN INC

NASDAQ:PGEN (3/6/2025, 11:59:07 AM)

1.905

-0.02 (-1.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners66.46%
Inst Owner Change1.26%
Ins Owners2.71%
Ins Owner Change2.58%
Market Cap557.92M
Analysts80
Price Target6.46 (239.11%)
Short Float %7.24%
Short Ratio8.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6%
Min EPS beat(2)-10.29%
Max EPS beat(2)-1.7%
EPS beat(4)0
Avg EPS beat(4)-22.09%
Min EPS beat(4)-64.45%
Max EPS beat(4)-1.7%
EPS beat(8)1
Avg EPS beat(8)-10.33%
EPS beat(12)4
Avg EPS beat(12)-29.61%
EPS beat(16)6
Avg EPS beat(16)-20.07%
Revenue beat(2)0
Avg Revenue beat(2)-35.18%
Min Revenue beat(2)-45.1%
Max Revenue beat(2)-25.25%
Revenue beat(4)0
Avg Revenue beat(4)-32.25%
Min Revenue beat(4)-45.1%
Max Revenue beat(4)-25.25%
Revenue beat(8)0
Avg Revenue beat(8)-34%
Revenue beat(12)0
Avg Revenue beat(12)-47.88%
Revenue beat(16)2
Avg Revenue beat(16)-44.11%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)8.71%
EPS NQ rev (3m)14.24%
EPS NY rev (1m)0%
EPS NY rev (3m)1.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 140.78
P/FCF N/A
P/OCF N/A
P/B 10.08
P/tB 21.72
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.01
BVpS0.19
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -167.19%
ROE -252.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.34%
ROA(5y)-40.18%
ROE(3y)-48.15%
ROE(5y)-169.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.89%
Cap/Sales 217.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.63
Quick Ratio 1.63
Altman-Z -26.19
F-Score3
WACC9.12%
ROIC/WACCN/A
Cap/Depr(3y)40.47%
Cap/Depr(5y)63.3%
Cap/Sales(3y)31.22%
Cap/Sales(5y)28.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y-21.88%
EPS Next 2Y20.88%
EPS Next 3Y30.58%
EPS Next 5Y24.74%
Revenue 1Y (TTM)-41.38%
Revenue growth 3Y-60.78%
Revenue growth 5Y-47.17%
Sales Q2Q%-30.89%
Revenue Next Year-38.3%
Revenue Next 2Y79.23%
Revenue Next 3Y188.95%
Revenue Next 5Y125.76%
EBIT growth 1Y-9.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-50.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.84%
OCF growth 3YN/A
OCF growth 5YN/A